Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Generalitat Valenciana, Fundació La Marató de TV3, Instituto de Salud Carlos III, Societat Catalana de Cardiologia, European Regional Development Fund, Agència Valenciana de la Innovació, Ministerio de Economía y Competitividad, Marcos-Garces, Victor, Gavara, Jose, Lopez-Lereu, Maria P., Monmeneu, Jose V., Rios-Navarro, Cesar, De Dios, Elena, Pérez, Nerea, Cànoves, Joaquim, Gonzalez, Jessika, Minana, Gema, Nunez, Julio, de la Espriella, Rafael, Santas, Enrique, Moratal, David, Chorro, Francisco J., Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Generalitat Valenciana, Fundació La Marató de TV3, Instituto de Salud Carlos III, Societat Catalana de Cardiologia, European Regional Development Fund, Agència Valenciana de la Innovació, Ministerio de Economía y Competitividad, Marcos-Garces, Victor, Gavara, Jose, Lopez-Lereu, Maria P., Monmeneu, Jose V., Rios-Navarro, Cesar, De Dios, Elena, Pérez, Nerea, Cànoves, Joaquim, Gonzalez, Jessika, Minana, Gema, Nunez, Julio, de la Espriella, Rafael, Santas, Enrique, Moratal, David, and Chorro, Francisco J.
[EN] Background Cardiac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation myocardial infarction patients, but its indiscriminate use in all cases is not feasible. We evaluated the utility of left ventricular ejection fraction (LVEF) by echocardiography for a selective use of CMR after ST-segment-elevation myocardial infarction. Methods Echocardiography and CMR were performed in 1119 patients discharged for ST-segment-elevation myocardial infarction included in a multicenter registry. The prognostic power of CMR beyond echocardiography-LVEF was assessed using adjusted C statistic, net reclassification improvement index, and integrated discrimination improvement index. Results During a 4.8-year median follow-up, 136 (12%) first major adverse cardiac events (MACE) occurred (47 cardiovascular deaths and 89 readmissions for acute heart failure). In the entire group, CMR-LVEF (but not echocardiography-LVEF) independently predicted MACE occurrence. The MACE rate significantly increased only in patients with CMR-LVEF<40% (>= 50%: 7%, 40%-49%: 9%, <40%: 27%, P<0.001). Most patients displayed echocardiography-LVEF >= 50% (629, 56%), and they had a low MACE rate (57/629, 9%). In patients with echocardiography-LVEF<50% (n=490, 44%), the MACE rate was also low in those with CMR-LVEF >= 40% (24/278, 9%) but significantly increased in patients with CMR-LVEF<40% (55/212, 26%; P<0.001). Compared with echocardiography-LVEF, CMR-LVEF significantly improved MACE prediction in the group of patients with echocardiography-LVEF<50% (C statistic, 0.80 versus 0.72; net reclassification improvement index, 0.73; integrated discrimination improvement index, 0.10) but not in those with echocardiography-LVEF >= 50% (C statistic 0.66 versus 0.66; net reclassification improvement index, 0.17; integrated discrimination improvement index, 0.01). Conclusions A straightforward strategy based on a selective use of CMR for risk prediction in ST-segment-elevati